I thought I would post a note on the EMBL-EBI's Industry Programme. This is a forum open to all life-science companies to network and understand the tools, resources and direction of the EMBL-EBIs activities, and also encourage discussion of pre-competitive and collaborative activities between life-science companies. Given the increasing demands for cost-reduction, data integration and knowledge representation within the sector this activity is becoming increasingly important. Details of how to join the can be found on the EMBL-EBI web-site (link above). An analogous group exists for smaller companies (SME/SMBs).
We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains: 2,431,025 compounds (of which 2,409,270 have mol files) 3,106,257 compound records (non-unique compounds) 20,772,701 activities 1,644,390 assays 15,598 targets 89,892 documents Data can be downloaded from the ChEMBL FTP site: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release: https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.
Comments